Directorate Update

RNS Number : 8094Q

Oxford BioDynamics PLC

15 September 2017

 

15 September 2017

Oxford BioDynamics Plc

Directorate update

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that further to the announcement on 30 June 2017, Paul Stockdale will join the Company as Chief Financial Officer and an Executive Director on the Board, with immediate effect.

For further details contact:

Oxford BioDynamics Plc		[phone]
Christian Hoyer Millar, CEO
Paul Stockdale, CFO
Stifel Nicolaus Europe Limited		[phone]
Nominated Advisor and Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital		[phone]
Joint Broker
Bidhi Bhoma
Edward Mansfield
FTI Consulting		[phone]
Financial Public Relations Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins

Appendix - Schedule Two Information

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Paul Leslie Stockdale, aged 42 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships	Past Directorships
None	PL & JE Services Limited

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

BOABUGDCBXBBGRS